TG THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M |
| Cost of revenue | $100.7M | $38.5M | $14.1M | $265,000 | $790,000 |
| Selling, general & administrative | $232.0M | $154.3M | $122.7M | $95.5M | $128.1M |
| Research and development | $160.2M | $94.3M | $76.2M | $125.4M | $222.6M |
| Operating expenses | — | — | — | $195.6M | $351.5M |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M | -$344.8M |
| Interest expense | $26.7M | $24.0M | $12.6M | $10.2M | $5.6M |
| Pretax income | $107.4M | $25.6M | $13.1M | -$223.8M | -$348.1M |
| Income tax expense | -$339.8M | $2.2M | $390,000 | $0 | $0 |
| Net income | $447.2M | $23.4M | $12.7M | -$223.8M | -$348.1M |
| Balance Sheet | |||||
| Cash and equivalents | $79.1M | $179.9M | $92.9M | $102.3M | $298.9M |
| Current assets | $630.8M | $566.4M | $317.9M | $168.3M | $331.0M |
| Total assets | $1.1B | $577.7M | $329.6M | $193.6M | $379.6M |
| Current liabilities | $153.8M | $90.7M | $53.7M | $53.2M | $65.4M |
| Total liabilities | $415.2M | $355.3M | $169.1M | $135.0M | $142.5M |
| Total debt | — | — | $105.2M | $76.7M | — |
| Stockholders' equity | $648.0M | $222.4M | $160.5M | $58.6M | $237.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$24.8M | -$40.5M | -$31.4M | -$176.2M | -$295.6M |
| Depreciation and amortization | $59,000 | $68,000 | $211,000 | $303,000 | $282,000 |
| Stock-based compensation | $64.7M | $42.5M | $37.9M | $44.7M | $61.3M |
| Capital expenditure | $214,000 | $45,000 | $0 | $14,000 | $401,000 |
| Free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M | -$296.0M |
| Share repurchases | $91.2M | $8.8M | $0 | $0 | — |
| Impairments | — | — | — | $0 | $0 |
Shares outstanding 153.1M · Free float 78.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.